Status:
UNKNOWN
The Efficacy and Safety of a Combination Therapy of Rosuvastatin and Ezetimibe Versus Monotherapy of Rosuvastatin in Hypercholesterolemia Patients
Lead Sponsor:
IlDong Pharmaceutical Co Ltd
Conditions:
Hypercholesterolemia
Eligibility:
All Genders
19-80 years
Phase:
PHASE3
Brief Summary
To evaluate efficacy and safety of a combination therapy of rosuvastatin and ezetimibe versus monotherapy of rosuvastatin in hypercholesterolemia patients
Detailed Description
To evaluate efficacy and safety of a combination therapy of rosuvastatin and ezetimibe versus monotherapy of rosuvastatin in hypercholesterolemia patients
Eligibility Criteria
Inclusion
- Hypercholesterolemic patient
Exclusion
- Has history of hypersensitivity to HMG-CoA reductase inhibitor and Ezetimibe
Key Trial Info
Start Date :
July 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT02251847
Start Date
July 1 2014
Last Update
September 29 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Gil Medical Center
Seoul, South Korea